| Autor: |
Pevzner AM; Tomsk National Research Medical Center of the Russian Academy of Sciences, Oncology Research Institute, Tomsk, Russia., Tsyganov MM; Tomsk National Research Medical Center of the Russian Academy of Sciences, Oncology Research Institute, Tomsk, Russia., Ibragimova MK; Tomsk National Research Medical Center of the Russian Academy of Sciences, Oncology Research Institute, Tomsk, Russia., Litvyakov NV; Tomsk National Research Medical Center of the Russian Academy of Sciences, Oncology Research Institute, Tomsk, Russia. |
| Jazyk: |
ruština |
| Zdroj: |
Vestnik otorinolaringologii [Vestn Otorinolaringol] 2020; Vol. 85 (2), pp. 67-72. |
| DOI: |
10.17116/otorino20208502167 |
| Abstrakt: |
The review is devoted to assessing the prevalence of human papillomavirus (HPV) in combination with other viral agents for head and neck tumors (HNT). HPV is recognized as an etiological factor in the development of cervical cancer, but there is evidence that it may be involved in carcinogenesis in other locations, in particular the upper respiratory tract. However, HPV is not the most important factor in tumor growth and progression. Recently, many researchers have reported the presence of concomitant co-infection, affecting tumor progression. Of all the studies analyzed, only 3 studies showed the absence or low rates of co-infection in HNT: from the Czech Republic (0%), China (0.6%) and Japan (3%). Most often, HPV infection was detected together with the Epstein-Barr virus (EBV) - from 12.5 to 34.1% of cases. In Russia, the prevailing combination of viral co-infection was a combination of EBV and cytomegalovirus (9.5%) and a combination of EBV and herpes simplex virus (6.7%). Thus, the degree of incidence of HPV in HNT varies greatly, and the mechanisms of coinfection are poorly understood, which raises the question of whether HPV and concomitant infection can be involved in tumor progression. This makes further research in this direction relevant and promising. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
